Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciprofloxacin/fluocinolone acetonide - SALVAT

Drug Profile

Ciprofloxacin/fluocinolone acetonide - SALVAT

Alternative Names: Cetraxal Comp; Cetraxal Plus; DF277/DF289; DF289/DF277; Duoxal; Fluocinolone acetonide/ciprofloxacin; Infalin Duo; Otixal; Otixal®; Otospon; Otovel; OTOVEL; Ultramicina Plus

Latest Information Update: 24 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SALVAT
  • Developer Arbor Pharmaceuticals; Medexus Pharmaceuticals; SALVAT
  • Class Anti-inflammatories; Antibacterials; Eye disorder therapies; Fluorinated steroids; Fluoroquinolones; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis externa; Otitis media

Most Recent Events

  • 24 Sep 2021 No development reported - Preregistration for Otitis externa in Canada (Otic)
  • 19 Nov 2020 Lee's Pharmaceutical plans a phase III trial for Otitis externa (In children, In adolescent, In adult, In the elderly) in China, in November 2020 , (NCT04636957)
  • 13 Dec 2018 Pediapharm is now called Medexus Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top